The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; BioNTech; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Immunomic Therapeutics; Loxo; Merck; Pfizer; Vaccinex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst); VentiRx (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - ISA Pharmaceuticals; Nanobiotix
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; CUE Biopharma; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Exelixis (Inst); Innate Pharma (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst)
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Doxapharma; Eisai; GlaxoSmithKline; Incyte; Ipsen; Merck Serono; MSD; Nanobiotix; Novartis; Roche; SOBI
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Serono; MSD
 
Justine Yang Bruce
Leadership - ImageMoverMD (I)
Stock and Other Ownership Interests - ImageMoverMD (I)
Consulting or Advisory Role - Genzyme
Research Funding - Incyte (Inst); Kura Oncology (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Sensei Biotherapeutics (Inst)
 
Maura L. Gillison
Consulting or Advisory Role - Bayer; Bicara Therapeutics; BioNTech; BioNTech; Bristol-Myers Squibb; Debiopharm Group; EMD Serono; Gilead Sciences; Ipsen; Kura Oncology; Merck; Roche; Shattuck Labs
Research Funding - Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genocea Biosciences (Inst)
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Lilly; MSD; TAKEDA
Consulting or Advisory Role - Alpha pharmaceutical; AstraZeneca; Boehringer Ingelheim; Lilly; MSD; TAKEDA
 
Ching-Yun Hsieh
No Relationships to Disclose
 
Hung-Ming Wang
No Relationships to Disclose
 
Amanda Psyrri
Honoraria - AstraZeneca; Bayer; BMS; Genesis Pharmaceuticals; Merck Serono; MSD Oncology; Pfizer; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; eTheRNA immunotherapies; MSD Oncology; Pfizer; Rakuten Medical
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Ipsen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; AstraZeneca
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - ALX Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; Debiopharm Group; Incyte; Innate Pharma; Janssen; Merck Serono; Merck Sharp & Dohme; Nanobiotix; Novartis; Pfizer; Roche
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Binaifer Balsara
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
 
Mollie Leoni
Employment - Kura Oncology; Kyowa Kirin International
Stock and Other Ownership Interests - Kura Oncology
Travel, Accommodations, Expenses - Kura Oncology; Kura Oncology; Kyowa Kirin International
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Vyriad (Inst)
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Replimune (Inst); Vyriad (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst)
 
Nabil F. Saba
Honoraria - BioNTech; CUE Biopharma; Merck
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Blueprint Medicines; GlaxoSmithKline; Merck; Pfizer
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck